@article {Weissenrieder532788, author = {Jillian S. Weissenrieder and Jessie L. Reed and Jeffrey D. Neighbors and Raymond J. Hohl}, title = {Thioridazine as an Anticancer Therapeutic: Interplay with the Isoprenoid Biosynthetic Pathway}, elocation-id = {532788}, year = {2019}, doi = {10.1101/532788}, publisher = {Cold Spring Harbor Laboratory}, abstract = {Glioblastoma multiforme is a form of cancer with poor survival prognosis and few treatment options. The cerebrovascular barrier complicates the delivery of chemotherapeutic agents and contributes to poor treatment response in patients with this disease. Recently, dopamine D2 receptor antagonizing compounds, including the FDA-approved phenothiazine, thioridazine, were identified as potential anticancer therapeutics, but their mechanism of action is as yet poorly understood. We investigated the hypothesis that the cytotoxicity of thioridazine may be tied to disruption of lipid metabolism, specifically the synthesis of isoprenoids and cholesterol by the isoprenoid biosynthetic pathway. We show that, while pathway inhibitors lovastatin and zoledronate can sensitize U87MG and U251MG cells to thioridazine treatment, the addition of pathway intermediates cannot prevent thioridazine{\textquoteright}s cytotoxic effects. Treatment with methyl-schweinfurthin G, which is known to disrupt lipid trafficking, is able to sensitize these cell lines as well, suggesting that cholesterol availability or localization may be involved in these effects. However, all measured effects were of very small, biologically insignificant magnitude and thus findings are of limited utility.}, URL = {https://www.biorxiv.org/content/early/2019/01/29/532788}, eprint = {https://www.biorxiv.org/content/early/2019/01/29/532788.full.pdf}, journal = {bioRxiv} }